Survival characteristics of myelodysplastic syndrome with U2AF1mutation and the clinical efficacy of arsenic-containing traditional Chinese medicine compound prescription
“据最新研究,U2AF1突变与骨髓增生异常综合征临床特征密切相关,年龄是影响患者预后的重要因素。”
北京中医药大学学报2025年48卷第9期 页码:1211-1221
作者机构:
作者简介:
张朝畅,男,在读博士生
通信作者:唐旭东,男,博士,主任医师,博士生导师,主要研究方向:中西医结合防治血液病,E-mail:tangxudong001@163. com
基金信息:
国家自然科学基金面上项目;National Natural Science Foundation of China(No.82074258;No.82274502);第二批北京市研究型病房示范建设项目(No.BCRW202108);中国中医科学院科技创新工程重大攻关项目(No.CI2021A01701)
ZHANG Chaochang, LIU Chi, WANG Dexiu, et al. Survival characteristics of myelodysplastic syndrome with U2AF1mutation and the clinical efficacy of arsenic-containing traditional Chinese medicine compound prescription[J]. Journal of Beijing University of Traditional Chinese Medicine, 2025, 48(9): 1211-1221.
ZHANG Chaochang, LIU Chi, WANG Dexiu, et al. Survival characteristics of myelodysplastic syndrome with U2AF1mutation and the clinical efficacy of arsenic-containing traditional Chinese medicine compound prescription[J]. Journal of Beijing University of Traditional Chinese Medicine, 2025, 48(9): 1211-1221. DOI: 10.3969/j.issn.1006-2157.2025.09.005.